Merck & Co. Inc. buy geldnutzer
Start price
22.12.19
/
50%
€83.00
Target price
04.11.21
€79.00
Performance (%)
-3.61%
End price
05.11.21
€80.00
Summary
This prediction ended on 05.11.21 with a price of €80.00. With a performance of -3.61%, the BUY prediction for Merck & Co. Inc. by geldnutzer closed slightly in the red. A total of €3.76 was paid as dividends for this prediction. geldnutzer has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Merck & Co. Inc. | 0.382% | 0.382% | 4.167% | 71.261% |
iShares Core DAX® | 0.347% | 2.173% | 18.599% | 21.611% |
iShares Nasdaq 100 | 0.715% | 0.138% | 26.542% | 40.349% |
iShares Nikkei 225® | 1.522% | 2.003% | 13.220% | 3.542% |
iShares S&P 500 | 0.631% | 1.633% | 25.009% | 42.942% |
According to geldnutzer what are the pros and cons of Merck & Co. Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Undervalued
High dividend yield expected
positive Cash Flow expected
Good rating
Valuable balance sheet
ROE higher than 10% per year
Very good company culture
Leading role in innovation
Very differentiated customer and product portfolio
Growths faster than the competition
Stable Large shareholder and/or long term investor
Top 10 in its market
Small cyclical dependencies
Well known brand
Very Future proof/growth oriented business model
Standard Investments for future growth
Normal challenges to pay loans and raise capital
Very capable Management
Strong uniques
Sustainability is important
Medium risks for its business
Cons
Comments by geldnutzer for this prediction
In the thread Merck & Co. Inc. diskutieren
Buy mit Kursziel 99,0
Kursziel geändert auf 79,0
Kursziel geändert auf 89,0
Kursziel geändert auf 79,0
Kursziel geändert auf 72,0
Kursziel geändert auf 74,0
Kursziel geändert auf 64,0
Kursziel geändert auf 69,0
Kursziel geändert auf 76,0
Kursziel geändert auf 79,0
In the thread Trading Merck & Co. Inc.
Die von geldnutzer gewählte maximale Laufzeit wurde überschritten